Chitosan Formulations for Solubility and Bioactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chitosan's bioactivity and solubility in various applications are hindered by its insolubility in most organic solvents and its rapid depolymerization in environments with lysozyme, limiting its targeted use in medical and industrial applications.
Innovation Solution
Aqueous chitosan-containing formulations are developed, comprising chitosan, an acid to enhance solubility, and deionized water, optionally with a polyol, which are suitable for administration and can be formulated into solutions or gels with controlled viscosity, allowing for targeted applications such as wound treatment, antimicrobial use, and oral health promotion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chitosan is used in its natural form, then it maintains its inherent bioactivity and biocompatibility, but it is insoluble in most organic solvents which limits its application
Solution Approach 1:
The patent changes the chemical parameters of chitosan by controlling its degree of deacetylation (DDA) and molecular weight (MW) to optimize both solubility and bioactivity. By selecting specific DDA ranges (70-90%) and MW ranges (50,000-500,000 Daltons), the formulation achieves improved solubility in aqueous solutions while preserving the essential bioactive properties of chitosan for medical applications.
2Adaptability or versatility
If chitosan is administered in environments with lysozyme present, then it can be used in biological fluids and tissues, but rapid depolymerization occurs which reduces its effectiveness
Solution Approach 1:
The patent applies preliminary action by pre-modifying chitosan through controlled deacetylation to create a more stable molecular structure before administration. The specific DDA range of 70-90% creates a formulation that is more resistant to lysozyme-mediated depolymerization, thereby extending the duration of action and maintaining effectiveness in biological environments.
Solution Approach 2:
The patent creates a composite formulation by combining chitosan with specific excipients and buffers to form a stable aqueous solution. This composite approach enhances the overall stability of chitosan in biological environments, protecting it from rapid depolymerization while maintaining its therapeutic benefits.
3Reliability
If high molecular weight chitosan is used, then it maintains better structural integrity and bioactivity, but it has lower solubility and harder processing
Solution Approach 1:
The patent optimizes the molecular weight parameter to a specific range of 50,000-500,000 Daltons, which balances structural integrity with solubility. This parameter optimization allows the chitosan to maintain its bioactive conformation and structural stability while being sufficiently soluble for formulation and administration.
Solution Approach 2:
The patent applies local quality by creating regions of different deacetylation within the chitosan structure, with DDA ranging from 70-90%. This heterogeneous structure allows certain portions to maintain structural integrity while other portions enhance solubility, resolving the contradiction between these two properties.
4Adaptability or versatility
If low degree of deacetylation chitosan is used, then it has improved solubility, but it depolymerizes faster in biological environments
Solution Approach 1:
The patent identifies and applies an optimal DDA range of 70-90%, which balances solubility enhancement with stability maintenance. This parameter optimization ensures that the chitosan remains sufficiently soluble for formulation while being resistant enough to lysozyme degradation to maintain its therapeutic effect over the required duration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide effective antimicrobial properties, promote wound healing, reduce inflammation, and enhance skin and oral health by maintaining optimal moisture levels and inhibiting bacterial growth, while being adaptable for different application methods.
Implementation Method 1
an amount of at least one acid effective to enhance the solubility of said chitosan in deionized water
Implementation Method 2
mixing chitosan with an amount of acidified deionised water effective to solubilize said chitosan
Implementation Method 3
its bioactivity, which mainly relies on the physical interaction between this cationic molecule and the negative charge of the other component(s) being attracted thereto
Implementation Method 4
In certain environments where lysozyme is present (e.g., in biological fluids and tissues of many living organisms such as bacteria, plants, insects, birds, mammals, and the like), e.g. on skin, or in tears, saliva or mucous, depolymerization of chitosan will take place to release chitooligosaccharides and eventually N-acetylglucosamine and glucosamine
Implementation Method 5
depolymerization of chitosan will take place to release chitooligosaccharides and eventually N-acetylglucosamine and glucosamine
Data Source
AI summary
Provided herein are chitosan-containing formulations, methods of making such formulations, and methods of using such formulations. Chitosan contemplated for use herein is preferably of high quality and its source is preferably of crustacean origin. The formulations contemplated herein are aqueous, either liquid- or viscous-like, varying in concentration and type of chitosan and acid used, and may include other components. Their uses are diverse, for oral/dental administration or topical/surface application to subjects (e.g. humans or animals) in need thereof or even food commodities, aiming to maintain a good condition where it is applied or contributing to health enhancement, healing, disease prevention or treatment. The present invention also relates to concentrated solutions that may be used for the formulation of other products.